Effect of Adipose-Derived Mesenchymal Stem Cells on Treatment of Secondary Progressive Multiple Sclerosis Patients

Introduction: Multiple sclerosis (MS) is a chronic neurological disease in CNS which characterized by neuroinflammation and neurodegeneration with aggressive attack of auto-immune cells into myelin sheet axons and causes irreversible disability. Such damagesresult in gross pathological symptoms in affected young people. Although available strategies slow down MS progression but they aren’t effective for the progressive phase of disease. Mesenchymal stem cells are (MSCs) self-renewal cells due to their immune-modulatoryand neurogenerative traits have achieved fascinating prospects in regenerative medicine. Fat tissue is an optimal source of MSCs because of high abundance and high proliferative rate. Materials and Methods: The study is designed an open label phase1/2 trial by 10 female (SPMS). Eligible participants are, nonpregnant, unresponsive to other approved treatments, lack of chronic and acute infection or tumor. Patientsare predicted to continue to have progression of disease next year. Adipose tissue were removed, after isolation, expand their (AT-MSC) to reach to a range of 5×106 MSC/Kg of body weight. Then infuse their expanded AT-MSC in 2 dosages during 2 injection space 7 daysapart. The effect of AT-MSCs on patients were evaluated by assessment of EDSS on baseline, 2 weeks, 1, 3,6 and 9 months after first injection according to MacDonald criteria. Results: In all of patients EDSS was decreased significantly from baseline to 3 months post first injectionthere after EDSS was increases in 2 patients by 1 point at endpoint of follow up and 6 patients were progression free and in 2 patients EDSS was reduced significantly by 1 point from baseline to 9 months after first injection.Conclusion: MSCs were safe and effective in secondary progressive MS patients and the most pronounced influence was from baseline to 3 months after first MSC administration.